Pyrrolidines as NK3 receptor antagonists

US8394834B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Philippe Jablonski · Steinbrunn-le-Haut, FR
• Henner Knust · Rheinfelden (Baden), DE
• Matthias Nettekoven · Weil am Rhein, DE
• Angelique Patiny-Adam · Kembs, FR
• Hasane Ratni · Habsheim, FR
• Claus Riemer · Glückstadt, DE

Key dates

• Filing date: Aug 16, 2010
• Grant date: Mar 12, 2013
• Expiry date: Nov 6, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a compounds of formula Iwherein R1, R2, Ar1, Ar2, R′, R″, m, n, and o are defined in the specification or to a pharmaceutically active salt, racemic mixture, enantiomer, optical isomer or to tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).